Previda® is a laboratory test performed on embryos as part of in vitro fertilization (IVF) cycles to evaluate chromosome copy number. The analysis screens for chromosome aneuploidies, such as missing or extra chromosomes (monosomies or trisomies). PGT-A is intended solely for the assessment of chromosome copy number and does not test for single-gene disorders. For testing of specific single-gene conditions, please refer to PGT-M.
PGT-A helps identify chromosomally abnormal embryos and may be used for patients who fall into the following groups:
Your Providers
Order PGT-A
You Begin Treatment
At Your IVF Clinic
Embroys Are
Created & Biopsied
At Your IVF Clinic
Clinic Ships Biopsies to
Progenisis. Your Embryos
Remain at the Clinic
Progenesis Perform
PGT-A
Results Are Released
To Your Provider
Genetic Counseling
Is Available Through Progenesis
PGT-A+ (Preimplantation Genetic Testing for Aneuploidies Plus) builds on standard embryo screening by adding an extra DNA-level check that a microscope alone cannot provide.
Standard embryo testing looks at chromosome numbers — the goal being to identify embryos with the normal 46 chromosomes that may be suitable for transfer. But visual assessment at the time of fertilization doesn’t always tell the full story. After fertilization, embryologists observe structures called pronuclei (PN) inside the egg. An embryo that looks abnormal under the microscope may actually be chromosomally normal — and an embryo that looks perfectly healthy may carry a hidden abnormality.
PGT-A+ uses SNP (Single Nucleotide Polymorphism) technology to confirm the true chromosome count of each embryo, going beyond what can be seen visually.
For physicians managing IVF cycles, visual pronuclear assessment alone introduces a meaningful rate of embryo misclassification and the consequences fall directly on your patients. Chromosomal abnormalities like triploidy and haploidy have been linked to failed implantation, early pregnancy loss, and transfers that prenatal screening will later flag as problematic. Without DNA-level confirmation, viable embryos are discarded and hidden abnormalities go undetected, not because of clinical error, but because the microscope simply cannot see what SNP technology can.
PGT-A+ closes that gap with no added burden to your existing protocol. It runs on the same biopsy sample already collected during standard PGT-A with no extra procedures and no disruption to your workflow. Results are delivered within 10 to 15 business days, giving your team a clear, confident basis for transfer decisions. For clinics committed to maximizing outcomes and minimizing avoidable loss, it is the most practical and meaningful upgrade available to your current screening process.
PGT-A tests assess a small number of cells present in the trophectoderm of an embryo. It is not necessarily a representation of the entire embryo.
At Progenesis, you are at the heart of everything we do. Your questions and concerns matter to us, and we’re here to provide the answers and support you need. Your journey to a healthy family starts with us.
